Denise Uyar

938 total citations
43 papers, 664 citations indexed

About

Denise Uyar is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Denise Uyar has authored 43 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 22 papers in Reproductive Medicine and 10 papers in Obstetrics and Gynecology. Recurrent topics in Denise Uyar's work include Ovarian cancer diagnosis and treatment (22 papers), Endometrial and Cervical Cancer Treatments (9 papers) and BRCA gene mutations in cancer (5 papers). Denise Uyar is often cited by papers focused on Ovarian cancer diagnosis and treatment (22 papers), Endometrial and Cervical Cancer Treatments (9 papers) and BRCA gene mutations in cancer (5 papers). Denise Uyar collaborates with scholars based in United States, Spain and Canada. Denise Uyar's co-authors include Janet S. Rader, Heidi E. Frasure, Maurie Markman, Vivian E. von Gruenigen, Sharon Mount, Gamal H. Eltabbakh, William H. Bradley, William E. Brady, Panagiotis A. Konstantinopoulos and Paul J. Goodfellow and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Denise Uyar

40 papers receiving 647 citations

Peers

Countries citing papers authored by Denise Uyar

Since Specialization

Citations

This map shows the geographic impact of Denise Uyar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise Uyar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise Uyar more than expected).

Fields of papers citing papers by Denise Uyar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise Uyar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise Uyar. The network helps show where Denise Uyar may publish in the future.

Co-authorship network of co-authors of Denise Uyar

This figure shows the co-authorship network connecting the top 25 collaborators of Denise Uyar. A scholar is included among the top collaborators of Denise Uyar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise Uyar. Denise Uyar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	749P Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study 2024 ·Annals of Oncology ·Lainie P. Martin, Denise Uyar, Ainhoa Madariaga, Alexander I. Spira, Ana Oaknin, Russell J. Schilder, Eva María Guerra Alia, Erika Hamilton, R. Wendel Naumann, Domenica Lorusso, Lin Lü, (unknown), (unknown), John W. Moroney	1
2	PO13 2023 ·Brachytherapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Erin Bishop, (unknown), William H. Bradley, Denise Uyar, Janet S. Rader, Meena Bedi, Bradley A. Erickson	1
3	Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. 2023 ·Journal of Clinical Oncology ·Ana Oaknin, Lorena Fariñas-Madrid, (unknown), Lainie P. Martin, David M. O’Malley, Russell J. Schilder, Denise Uyar, John W. Moroney, John P. Diaz, Alexander I. Spira, Jesús García-Donás, (unknown), (unknown), (unknown), (unknown), R. Wendel Naumann	21
4	Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers 2021 ·The Application of Clinical Genetics ·(unknown), (unknown), Denise Uyar	16
5	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer 2020 ·Clinical Cancer Research ·Amit M. Oza, Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, Marcia Hall, Frederik Marmé, Diane Provencher, Denise Uyar, Johanne I. Weberpals, Robert M. Wenham, Naomi Laing, Michaël Tracy, Tomoko Freshwater, (unknown), Liu Ji, Jingjun Qiu, Shelonitda Rose, Eric H. Rubin, Kathleen N. Moore	89
6	Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling 2020 ·Cancer Research ·Deepak Parashar, (unknown), Anjali Geethadevi, Jasmine George, Ajay Nair, Shirng‐Wern Tsaih, (unknown), Gopa Kumar Gopinadhan Nair, Yiling Lu, Ramani Ramchandran, Denise Uyar, Janet S. Rader, Prahlad T. Ram, Gordon B. Mills, Sunila Pradeep, Pradeep Chaluvally–Raghavan	29
7	Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers 2020 ·Cancer Research ·R. Wendel Naumann, Denise Uyar, John W. Moroney, Fadi S. Braiteh, Russell J. Schilder, John P. Diaz, Erika Hamilton, Sami Diab, Lainie P. Martin, David M. O’Malley, Richard T. Penson, Clifford DiLea, (unknown), Venita DeAlmeida, Shannon Matheny, Arturo Molina	2
8	138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC) 2020 ·R. Wendel Naumann, Fadi Braiteh, John P. Diaz, Erika Hamilton, Sami Diab, Russell J. Schilder, John W. Moroney, Lainie P. Martin, Denise Uyar, David M. O’Malley, Richard T. Penson, Clifford DiLea, (unknown), Venita DeAlmeida, (unknown), Shannon Matheny, A. Molina	2
9	SOX11 hypermethylation as a tumor biomarker in endometrial cancer 2019 ·Biochimie ·(unknown), Denise Uyar, Li-Shu Wang, David G. Mutch, Tim H.‐M. Huang, Janet S. Rader, Xiugui Sheng, Yi‐Wen Huang	15
10	Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer 2019 ·International Journal of Gynecological Cancer ·Justin Harold, Denise Uyar, Janet S. Rader, Erin Bishop, (unknown), Pippa Simpson, William H. Bradley	8
11	Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer 2018 ·Gynecologic Oncology ·Denise Uyar, (unknown), Amy Monroe, Melodee Nugent, Pippa Simpson, Jennifer L. Geurts	20
12	A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer 2017 ·Annals of Oncology ·Kathleen N. Moore, Karen A. Cadoo, Suzanne K. Chambers, Sharad Ghamande, Gottfried E. Konecny, Amit M. Oza, LM Chen, Panagiotis A. Konstantinopoulos, Jayanthi Lea, Daniel L. Spitz, Denise Uyar, Ganesh Mugundu, Naomi Laing, Donald K. Strickland, Suzanne F. Jones, Howard A. Burris, David R. Spigel, Erika Hamilton	2
13	Utilization of Peer Teen Advocates to Increase Awareness of Human Papillomavirus and Vaccination among Urban Youth 2015 ·Denise Uyar, Staci Young, (unknown), (unknown)	1
14	An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer. 2015 ·Journal of Clinical Oncology ·Amit M. Oza, Johanne I. Weberpals, Diane Provencher, Eva‐Maria Grischke, Marcia Hall, Denise Uyar, Maria Del Pilar Estevez-Diz, Frederik Marmé, (unknown), Per Rosenberg, Robert M. Wenham, Jingjun Qiu, (unknown), Ji Liu, Shelonitda Rose, Kathleen N. Moore	31
15	3-T MRI-based adaptive brachytherapy for cervix cancer: Treatment technique and initial clinical outcomes 2014 ·Brachytherapy ·Jordan Kharofa, Natalya Morrow, Tracy Kelly, Jason Rownd, E.S. Paulson, Janet S. Rader, Denise Uyar, William H. Bradley, Beth Erickson	25
16	Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells 2005 ·Cancer Research ·Luis Rojas‐Espaillat, Denise Uyar, Dale Grabowski, Jerome L. Belinson, Francis Lee, Renzo Canetta, Ronald Bukowski, Mahrukh K. Ganapathi, Ram Ganapathi	8
17	Treatment patterns by decade of life in elderly women (≥70 years of age) with ovarian cancer 2005 ·Gynecologic Oncology ·Denise Uyar, Heidi E. Frasure, Maurie Markman, Vivian E. von Gruenigen	81
18	Cardiac safety profile of prolonged (≥6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies 2004 ·Gynecologic Oncology ·Denise Uyar, Barbara Kulp, Gertrude Peterson, Kristine Zanotti, Maurie Markman, Jerome L. Belinson	36
19	False Positive Diagnosis in Conventional and Liquid-Based Cervical Specimens 2004 ·Acta Cytologica ·Sharon Mount, (unknown), Gamal H. Eltabbakh, Denise Uyar, Gladwyn Leiman	13
20	Positive predictive value of liquid-based and conventional cervical Papanicolaou smears reported as malignant 2003 ·Gynecologic Oncology ·Denise Uyar, Gamal H. Eltabbakh, Sharon Mount	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact